Search

Copyright of Egyptian Journal of Experimental Biology (Botany) is the property of Egyptian Society of Experimental Biology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose: Chitosan and its derivatives possess several unique properties relevant in the field of pharmaceutics and medicinal chemistry. This study aimed to evaluate the pharmaceutical performance of an innovative chitosan derivative, methyl acrylate chitosan bearing p-nitrobenzaldehyde (MA*CS*pNBA) Schiff base.Methods: The antibacterial activity of MA*CS*pNBA was tested against multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria using agar-well diffusion method. Anti-biofilm formation was analyzed using a microtitre plate. Antioxidant assays were performed to assess the scavenging activity of MA*CS*pNBA using DPPH, hydrogen peroxide, superoxide together with its reducing power activity. Anti-inflammatory activity was evaluated by albumin denaturation, membrane stabilization, and proteinase inhibition methods. MA*CS*pNBA was tested for its hemolytic efficiency on human erythrocytes. Cytotoxicity of MA*CS*pNBA was evaluated by MTT assay.Results: MA*CS*pNBA showed a significant performance as an antibacterial candidate against MDR bacteria, anti-biofilm, antioxidant and anti-inflammatory biomaterial, evidencing hemocompatibility and no cytotoxicity. It exhibited a significant negative correlation with biofilm formation by the MDR-PA-09 strain. Biological activities were found to be significantly concentration-dependent.Conclusions: the newly chitosan derivative MA*CS*pNBA showed to be promising for pharmaceutical applications, expanding the treatment ways toward skin burn infections since it allied excellent antibacterial, anti-biofilm, antioxidant, anti-inflammatory, hemocompatibility and absence of cytotoxic activities. [ABSTRACT FROM AUTHOR]

The Multidrug Drug Resistance (MDR) and Pan-Drug Resistance (PDR) remain an intractable challenge issue in public health, worldwide. Plant extracts-based biological macromolecules containing a diverse array of secondary metabolites could be potentially used as alternative approaches to control or limit MDR/PDR infections. Plants of the Solanaceae family exhibit a wide variety of secondary metabolites with antioxidant and antimicrobial properties, which render them a significant role in food and pharmaceutical applications. To our knowledge, this is the first report on phytochemical constituents, antioxidant, antimicrobial activities and in vivo toxicological safety of Lycium shawii leaf extracts. Results revealed that phenolics and flavonoids were found to be the most abundant compounds in all extracts. Antioxidant activity of extracts was measured using DPPH • and ABTS •+ assays and the methanol extract displayed superior scavenging activity (IC 50  = 0.06 and 0.007 mg/mL for DPPH • and ABTS •+ , respectively). Results of the GC-MS analysis revealed the identity of 10 compounds. Moreover, in vivo toxicological assessment can confirm the safety of L. shawii for use. Overall, L. shawii leaves are a promising natural source for the development of novel antimicrobial and antioxidant agents that could potentially combat clinical MDR/PDR pathogens., (© 2019 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC.)